IL6 and myeloid sarcoma: (58) are compatible with the trans-signaling model of higher protection against MS risk through increased sgp130-mediated downregulation of IL-6/sIL6R-dependent pro-inflammatory activities and highlight these MS risk SNPs as potential determinants of circulating sgp130.